The Board of Directors of the Atlanpole Biotherapies cluster elected on July 4, 2024 for 3 years

Board of Atlanpole Biotherapies

  • President: Franck GRIMAUD – Valneva
  • Executive vice-president: Jean-François BALDUCCHI –  Atlanpole
  • Vice-president Biotech: Eric Le Forestier – Naobios / Clean Biologics
  • Vice-president Digital: Marwan Touati – Parean Biotechnologies
  • Vice-presidente Clinical: Cécile Jaglin – CHU d’Angers / HUGO
  • Vice-president Academic research: Férid Haddad – Arronax
  • Vice-president International development: Franck Zal – Hemarina
  • Vice-president Partnership relations: Louis-Marie Bachelot – Gliocure
  • Treasurer: Odile Duvaux – Xenothera
  • Secretary: Frédéric Ossant – CHU de Tours

Private College

  • Louis-Marie Bachelot – GLIOCURE
  • Jean-Marie Charpin – GENSENSOR
  • Isabelle Dimier-Poisson – LOVALTECH
  • Odile Duvaux – XENOTHERA
  • Benoit Fouchaq – BIOFORTIS EUROPE
  • Franck Grimaud – VALNEVA
  • Ulrich Jarry – BIOTRIAL
  • Eric Le Forestier – NAOBIOS / CLEAN BIOLOGICS
  • Olivier Lépine – ALGOSOURCE
  • Nicolas Poirier – OSE IMMUNOTHERAPEUTICS
  • Marwan Touati – PAREAN BIOTECHNOLOGIES
  • Franck Zal – HEMARINA

Higher education schools, research and care College

  • Etienne Bendjebbar – CHU DE NANTES
  • David Bigaud – UNIVERSITÉ D’ANGERS
  • Férid Haddad – GIP ARRONAX
  • Frédéric Jacquemin – NANTES UNIVERSITÉ
  • Guillaume Mercusot – INSTITUT DE CANCÉROLOGIE DE L’OUEST
  • Frédéric Ossant – CHU DE TOURS
  • Charles Pineau – UNIVERSITÉ DE RENNES
  • Nicolas Riffet-Vidal – CHU D’ANGERS

Economic development structures College

  • Jean-François Balducchi – ATLANPOLE
  • Nelly Besnard – BIOTECH SANTÉ BRETAGNE
  • Emmanuel Lichou – ANGERS TECHNOPOLE
  • Fabien Riolet – POLEPHARMA